Horizon Pharma PLC (NASDAQ:HZNP) has been assigned an average recommendation of “Buy” from the fourteen brokerages that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and ten have issued a buy recommendation on the company. The average 1 year price target among brokers that have covered the stock in the last year is $18.64.
HZNP has been the subject of a number of research analyst reports. UBS Group set a $20.00 target price on shares of Horizon Pharma and gave the stock a “buy” rating in a research report on Thursday, November 30th. Cantor Fitzgerald set a $17.00 price objective on shares of Horizon Pharma and gave the company a “buy” rating in a research report on Friday, December 1st. BidaskClub raised shares of Horizon Pharma from a “hold” rating to a “buy” rating in a research report on Friday, December 22nd. ValuEngine downgraded shares of Horizon Pharma from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st. Finally, Mizuho raised shares of Horizon Pharma from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $12.00 to $18.00 in a research report on Friday, January 12th.
Several institutional investors and hedge funds have recently added to or reduced their stakes in HZNP. Ameriprise Financial Inc. lifted its stake in shares of Horizon Pharma by 419.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 2,127,694 shares of the biopharmaceutical company’s stock valued at $26,979,000 after buying an additional 1,717,841 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of Horizon Pharma by 105.5% during the 4th quarter. Renaissance Technologies LLC now owns 2,279,400 shares of the biopharmaceutical company’s stock valued at $33,279,000 after buying an additional 1,170,000 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Horizon Pharma by 18.6% during the 3rd quarter. Dimensional Fund Advisors LP now owns 7,433,330 shares of the biopharmaceutical company’s stock valued at $94,254,000 after buying an additional 1,167,722 shares in the last quarter. William Blair Investment Management LLC lifted its stake in shares of Horizon Pharma by 12.2% during the 4th quarter. William Blair Investment Management LLC now owns 8,826,079 shares of the biopharmaceutical company’s stock valued at $128,861,000 after buying an additional 958,414 shares in the last quarter. Finally, Two Sigma Investments LP purchased a new position in shares of Horizon Pharma during the 4th quarter valued at $7,443,000. Institutional investors own 85.77% of the company’s stock.
Horizon Pharma (HZNP) traded up $0.15 during trading hours on Friday, reaching $15.73. 1,565,052 shares of the company’s stock were exchanged, compared to its average volume of 1,860,000. The company has a debt-to-equity ratio of 1.91, a quick ratio of 1.52 and a current ratio of 1.63. Horizon Pharma has a fifty-two week low of $9.45 and a fifty-two week high of $16.02. The company has a market cap of $2,580.00, a P/E ratio of -5.28, a PEG ratio of 0.66 and a beta of 1.34.
Horizon Pharma (NASDAQ:HZNP) last posted its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.29 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $0.07. Horizon Pharma had a negative net margin of 38.87% and a positive return on equity of 18.44%. The business had revenue of $274.22 million during the quarter, compared to the consensus estimate of $264.48 million. During the same quarter in the previous year, the firm posted $0.64 EPS. The firm’s revenue was down 11.6% on a year-over-year basis. equities analysts predict that Horizon Pharma will post 1.43 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This piece was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/03/10/horizon-pharma-plc-hznp-receives-consensus-rating-of-buy-from-brokerages.html.
Horizon Pharma Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.